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Abstract
Background: The mean overall survival rate of children with diffuse intrinsic pontine glioma
(DIPG) is 9–11months, with current standard treatmentwith fractionated radiotherapy and adju-
vant chemotherapy. So far, novel therapeutic strategies have not yet resulted in significantly bet-
ter survival. The main source of energy for glioblastoma cells is glucose. Therefore, metabolic
alterations induced by the use of the extremely carbohydrate-restricted ketogenic diet (KD) as
adjuvant therapy are subject of interest in cancer research.
Procedure:This studyexplores the safety and feasibility of theKD in childrenwith recurrentDIPG
and no remaining treatment options. Safety was defined as the number of adverse effects. Feasi-
bilitywas defined as the number of patientswhowere able to use theKD for threemonths. Coping
of patients and parents wasmeasured with questionnaires.
Results: Three of 14 children referred to our hospital between 2010 and 2015 were included.
Twopatients completed the study, and one died before the end of the study. Hospitalizationswere
needed for placing a nasogastric tube (n= 1) and epileptic seizures (n= 1). Adverse effects related
to the diet weremild and transient. Parents were highly motivated during the study.
Conclusion: Use of KD is safe and feasible, but the effect on survival has to be proven in a larger
cohort of children who start the KD earlier after diagnosis, preferably as adjuvant therapy to
fractionated radiotherapy.
K EYWORDS
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1 INTRODUCTION
Theprognosis of childrenwithdiffuse intrinsic pontineglioma (DIPG) is
extremely poor. Fractionated radiotherapy (RT) is the treatment of first
choice, with a reportedmean overall survival duration of 9–11months.
Only 10% of patients survive longer than two years.1,2 Adding temo-
zolomide (TMZ) to RT has not yielded any significant improvement in
survival.3 Chemotherapeutic strategies have been tested, but it proves
to be difficult to get therapeutic agents across the blood–brain barrier
(BBB)withoutmajor toxic side effects.4 Moreover, even after trespass-
ing theBBB, the level of drug deliverymay vary greatly due to inconsis-
tent interstitial fluid pressure within the tumor.5,6
Abbreviations: CT, chemotherapy; DIPG, diffuse intrinsic pontine glioma; GI, gastrointestinal; GMFCS, gross motor functioning classification system; KD, ketogenic diet; LQ, liquid formula; MCT,
medium chain triglycerides; OSR, overall survival rate; RT, fractionated radiotherapy; TMZ, temozolomide; VOOK, Ouders van eenOverleden Kind
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Glioblastoma cells use glucose as their main source of energy,
which is derived from the anaerobic glycolytic pathway.7 In contrast
to normal brain cells, glioblastoma cells cannot compensate for glu-
cose restriction by metabolizing ketone bodies.8,9 In light of this,
metabolic alteration may be an alternative adjuvant treatment ther-
apy. The ketogenic diet (KD)—an extremely carbohydrate-restricted
diet—may be an option because it mimics the metabolic response to
starvation when ketones become themain fuel for the brain instead of
carbohydrates.
In mice with glioblastoma, the KD induced a significant reduc-
tion of tumor size compared with a standard diet. The reduction was
even more profound when the KD was combined with radiotherapy,
Pediatr Blood Cancer. 2018;e27561. wileyonlinelibrary.com/journal/pbc 1 of 7
https://doi.org/10.1002/pbc.27561
2 of 7 VANDER LOUW ET AL.
suggesting that KD potentiates the effect of radiotherapy.10–12 Stud-
ies in humans with different types of brain tumors—one case report
in adults, one in children,13,14 and a clinical study in adults15—indicate
that a KD is well tolerated without severe side effects.
TheKD is awell-established treatment option in childrenwith drug-
refractory epilepsy. So far, it has not been studied in children with
DIPG, and thus we do not know whether children with this rapidly
progressive disease are able to use and tolerate such a compliance-
demanding and strict diet.
We report a study exploring the feasibility and safety of the KD in
children with DIPG who show tumor progression and have no remain-
ing treatment options. The children initially used a full liquid KD ver-
sion to induce rapidly ketosis, which then was modified to a more
liberal KDwithmedium chain triglyceride (MCT) emulsion.
2 MATERIALS AND METHODS
In the period 2010–2015, we performed a prospective study in chil-
dren up to 18 years with recurrent DIPG with no remaining thera-
peutic options. The setting was the department of pediatric neurol-
ogy in the Erasmus MC-Sophia Children's Hospital University Medical
Centre Rotterdam.
Exclusion criteria were inability of parents to handle the diet and
language barrier to understand instructions.
This study was approved by the local Medical Ethical Committee
(NL2856807809). In addition, we received a positive response from
theOuders vaneenOverledenKind (VOOK)on theethical issueof pre-
scribing a KD in the palliative phase of DIPG.
The study protocol started after parents had provided informed
consent. Children older than 12 years also provided informed consent
themselves. To rapidly induce ketosis, the KDwas initiated as a full liq-
uid (LQ) KD formula with a 4:1 diet ratio (4 g fat opposite to 1 g pro-
tein plus carbohydrates) and used for maximal two weeks. The KD LQ
was offered in different recipes of 100 mL and 200 calories with sim-
ilar nutritional composition, which could be used exchangeable. When
ketone levels of 3 mmol/L were reached, the KD LQ formula was step-
wise modified into a KD (range diet ratio 1.5:1–2.0:1) with strictly cal-
culatedandpreparedmeals.MCTemulsionmixedwith low fatmilkwas
used several times a day in addition to themeals.
The study duration was three months. Patients and parents regu-
larly visited the outpatient clinic or were visited at home by the dieti-
cian for monitoring. Any required additional support (by phone and/or
email) during the study was provided on an individual basis. Figure 1
demonstrates a flow chart of the study protocol.
Feasibilitywas defined as the number of patients able to use theKD
for threemonths.
Safety was defined as the occurrence of adverse effects ≥2 grade
based on common terminology criteria of adverse events (CTCAE).16
Adverse effects (e.g., gastrointestinal complaints, fatigue) were all
noted in a study diary and evaluated weekly by the dietician. Ketone
and glucose levels, growth parameters, and the incidence of side
effects were recorded in a study diary following the national and
international KD guidelines for children with refractory epilepsy.17,18
Hyperketosiswasdefinedas>6mmol/L andhypoglycemiawasdefined
as<2.5mmol/L.
During neurological examination at baseline and at the end of the
study, the patients grossmotor functioningwas scored using theGross
Motor Functioning Classification System (GMFCS).19
By means of a self-designed, not validated, questionnaire of
15 questions administered at baseline and at the end of the study
period, we explored if and how parents and patients were able to
cope with the KD. The item scores could range from 1 to 5 and indi-
cated the level of difficulty (1 not difficult, 5 very difficult) experienced
when applying the KD in daily practice and coping with it. Other items
reflecting the level of received information and support could range
from 1 to 5, being not enough (1) or enough (5), or motivation to start
the study could range from 1 to 5, having no doubts (1) ormany doubts
(5). The coping questionnaire is shown in Supporting Information data.
2.1 Patients
During the study period March 2010–March 2015, ten children were
treated for DIPG in our center. Four children with DIPG treated in
other centers were referred to our center. During a visit, parents and
children were extensively informed about the study and study proce-
dures by the neurologist and dietician.
Of the 10 children treated for DIPG in our center, two patients died
in the second week of RT due to severe acute edema of the brain-
stem and had such severe neurological symptoms that further treat-
ment was not meaningful. Parents of six patients were very interested
in the KD at disease onset but decided against participation of their
child after recurrence of the tumor with severe and highly progressive
neurological deterioration. Due to a language barrier, parents of one
patient could not be appropriately instructed and the child was there-
fore excluded. Thus, only one of the 10 children treated forDIPG in our
center could be included (case 1).
Of the four patients referred from other centers, two could be
included (cases 2 and 3). Parents of one of the other two decided
against participation after being informed, and the other family lived
in Spain and could not be properly guided there.
Because of the limited number of included patients, data of this
study are presented as case descriptions.
2.2 Case descriptions
Case 1: A male diagnosed with DIPG at the age of 4.4 years started
RT within 3 weeks after diagnosis and received a dose of 44.8 Gy in
16 fractions. Progressive neurological symptoms were noted after six
stable months. Subsequently, he received three 5-day courses of TMZ
100mg/m2/day eachmonth. After initial stabilization, the neurological
abnormalities deteriorated again after five cycles of TMZ, and tumor
progression was confirmed on MRI. At this point, he was included in
our study at 5.3 years of age. His SD score for weight for height was
+0.05 and his height for age was+2.00.
The KD LQ formula was stepwise introduced to a maximum of
seven exchanges of 100 mL Ketocal LQ 4:1 ratio and 200 kcal. On
day 3, he showed hypoglycemia (glucose level, 2.4 mmol/L) combined
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Visits 2 -4: (weeks 1 - 11)
Full Liquid KD formula 4:1 ratio
-->stepwise introduction
In case ketone levels > 3 mmol/l
--> stepwise introduction of
KD with MCT emulsions
Dietician: weeks 1-11:
Home visits (4 x )
- Blood glucose and ketone measurements 
- Weight/ height
- Food diary; 3 days 
- Questionnaire of adverse effects once a week.
End of the study: (home visit by the team)
Visit 5: week 12  
Dietician:
- Blood glucose and ketone measurements
- Weight/ height
- Food diary; 3 days 
- Questionnaire of adverse effects
- Coping questionnaire
Paediatric neurologist:  neurological examination, GMFCS 
level
1 week after ending any tumour treatment
Visit 0: outpatient clinic
Oncologist; information on study procedures
Dietician: information on dietary treatment
Visit 1: (week 0, outpatient clinic)
Dietician: diet plan, education, indirect calorimetry, 
anthropometrics, coping questionnaire and
education ketone/glucose blood measurements, 
Paediatric neurologist:  neurological examination, GMFCS 
level
Eligible patients
N=14
Included patients
N=3
KD started
N=3
n=1
died (1)
Study concluded
N=2
Excluded n=11
-died (2)
-deterioration (6)
-language problem (1)
-second thoughts (1)
-living abroad (1)
F IGURE 1 Study flowchart
KD, ketogenic diet; MCT, medium triglycerides; GMFCS, gross motor function classification system
with hyperketosis (ketone level, 7.2 mmol/L). Because he vomited and
refused the LQ formula, the diet was stepwise changed into a KD of
1.6:1 diet ratio with solid food consisting of 48 grams of carbohydrates
and MCT (using total of 100 mL MCT fat emulsion/day), which elim-
inated these symptoms. Hyperketosis (without hypoglycemia) irregu-
larly occurred, which could be treated by dietary alterations. The KD
with MCT was well tolerated without side effects. He showed no sig-
nificant change in SD scores for weight for height (−0.35) or height for
age (+1.83) at the end of the study.
Items of coping questionnaire concerning diet application and daily
monitoring scored 2 at both timemoments, and use of LQ formula was
difficult (score 4). Parents stayed motivated during the study (score 2,
no doubts at both timemoments).
At the start of the KD, neurological examination showed a bilateral
abducens paresis, reduced hearing on the right side and a right pyrami-
dal paresis. The GMFCS was level 3. Rapid neurological deterioration
was noted at the end of the study period, and at 3months follow-up he
had bilateral abducens, facial and glossopharyngeal paresis, as well as
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a tetraparesis grade 2 on the right side and grade 1 on the left side. The
GMFCS level at 3months was 5.
Parents decided not to continue the diet after the study period. The
patient died 3.5 months after end of the KD study, 7 months after end
of regular therapy (OSR of 16.5months).
Case 2: A male diagnosed with DIPG at 11.1 years of age was
treated with RT combined with gemcitabine according to the protocol
of his local hospital. Fourmonths after diagnosis, progression of neuro-
logical symptoms was noted, and progression of the tumor was visible
on MRI, as well as an ependymal metastasis in the right ventricle. Par-
ents and patient refused further chemo- or radiotherapeutic options.
He was included into the KD study at the age of 11.6 years. At the
start of the study, his SD score for weight for height had declined to
−3.09 due to limited food intake and persistent vomiting despite med-
ical treatment.
The KD LQ formula was carefully introduced with a maximum of
four exchanges of 100 mL Ketocal LQ 4:1 ratio and 200 kcal and some
snacks (i.e., ketomuffin, slices of fish or eggwithmayonnaise) with total
diet ratio 3.5:1.When adequate ketosiswas reached, the dietwas step-
wisemodified into a KDof 1.75:1 diet ratio with solid foods and 35 g of
carbohydrates andMCT. TheMCTemulsion (at study termination 75%
of calculated goal of 100mL/day hadbeen achieved)waswell tolerated
and he stopped vomiting.
Ketone and glucose levels were within normal range. Weight gain
was not achieved; the SD score for weight for height remained at−3.0.
Parents expected no difficulties applying the diet in daily practice
(score 1) but expected it would be difficult for (score 5) them and for
their son to cope with the high level of monitoring and the use of LQ
formula (score 4) due to his medical situation. Nevertheless, parents
weremotivated to start the study (score 2).
At start of the study, neurological examination showed dysfunction
of the left trigeminal, abducens and facial nerves, a mild ataxia on the
left side, right hyperreflexia, and a pathological plantar reflex on the
right side. The GMFCS level was level 2.
Three weeks after the start of the KD study, he was admitted
to the hospital with a generalized tonic–clonic seizure that easily
responded to antiepileptic treatment. MRI now also showed extensive
leptomeningeal metastases but no hydrocephalus. Within 24 hours,
the level of consciousness severely decreased and he did not regain
consciousness. His parents decided to a nonintervention policy, and
two days later the patient died (OSR of 6.4months).
Case 3: A male diagnosed with DIPG at the age of 14.5 years was
treated with RT up to 54 Gy in 30 fractions. Three months later,
neurological symptoms progressed, and tumor progression was evi-
dent on MRI. He was subsequently included in the DIPG-01 phase
B treatment study of the VU University Medical Center, Amsterdam.
Treatment consisted of two weekly infusions of bevacizumab and
irinotecan and daily oral erlotinib. A smaller tumor mass was seen on
MRI two months after the start of this therapy. However, MRI scans
four months after the start of this study showed tumor progression
and, for this reason, treatment was stopped.
He was included into the KD study one month later at the age of
15.5 years. He showed borderline overweight: SD score for weight for
height was+2.16 and height for age was−0.31 SD.
The KD LQ formula was stepwise introduced to a maximum of
8.5 exchanges of 100 mL Ketocal LQ 4:1 ratio and 200 kcal and a
little snack with an overall diet ratio of 3.8:1. When adequate keto-
sis was reached, the diet was stepwise modified into a KD of 2.1:1
diet ratio with solid food consisting of 38 g of carbohydrates andMCT
(using total of 110 mL MCT fat emulsion/day). As neurological symp-
toms relentlessly progressed and MRI showed increase of tumor size
and enhancement with gadolinium with stable ventricle size, he was
offered a short course of irradiation in week 6 of the study initiated
by the oncologist of the referring center. He received five fractions of
4 Gy on the tumor. On explicit request of the patient and parents, the
KDwas continued.
During the period of reirradiation combined with steroids, the
ketone levels two times decreased below the adequate range,
2.3 mmol/L and 1.8 mmol/L, respectively, but normalized again after
steroid use was stopped. Ketogenic nasogastric tube feeding was
started in week 8 because of swallowing difficulty. At the end of the
study, the SD score forweight for height stabilized at+2 and height for
age was−0.41.
Items of coping questionnaire concerning diet application and daily
monitoring scored 1 at both time moments. Parents stayed motivated
during the study (score 1 at both timemoments).
Neurological examination at the start of the study did not show
aphasia or dysarthria. However, a right lateral gaze palsy and a cen-
tral facial paresis with no other abnormalities of the cranial nerveswas
present, aswell as a left pyramidal paresis grade 3 at the arm and grade
4 at the leg with left hyperreflexia and left pathological plantar reflex.
The GMFCS gradewas level 3.
After three months of KD, at the end of the study, the patient had
a good language comprehension but could neither speak nor swallow
and had a complete ocular paresis. He had a left limb paralysis and
limited use of the right hand, but just enough to use a communication
device. At this time, the GMFCS gradewas level 5.
This situation initially stabilized for some weeks, after which it
slowly progressed for theworse. The patient died 3.5months after the
end of the study (OSR of 18.7months).
Patient characteristic are given in Table 1 and treatment character-
istics in Table 2.
2.3 Safety parameters
In all three cases, laboratory tests in blood and urine showed no
abnormalities. One patient (case 1) experienced hyperketosis sev-
eral times during KD use despite dietary adjustments and showed
borderline hypoglycemia once during diet initiation. Hospitalizations
were needed for placing a nasogastric tube (case 2) and epilepsy
management (case 3) andwas in both cases not related to the diet.
2.4 Coping
Parents were highly motivated to start the diet and continued being
so. In daily practice, they had no problemswith calculating and prepar-
ing the KD liquid exchanges or meals of solid food. The children them-
selves liked the KD with MCT better than the LQ formula, and it was
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TABLE 1 Patient characteristics
GMFCS
Growth-Weight/height-
Height/age(SD)
Patient Gender
Age at
diagnosis
(years)
Age at start
ketogenic diet
(years)
Treatment
characteristics
Start of
study
(level)
End of
study
(level) Start End
Overall
survival rate
(months)
1 M 4.4 5.3 - TMZ (tablets)
- RT
3 5 W+ 0.05
H+ 2.00
− 0.35
+ 1.83
16.5
2 M 11.0 11.6 - GCB
- (iv and tablets)
- RT
2 – W− 3.09
H− 0.71
–
–
6.4
3 M 14.4 15.5 - TMZ (tablets)
- RT
- Prednisolone
3 5 W+ 2.16
H− 0.31
+ 2.10
− 0.41
18.7
Abbreviations: GCB, gemcitabine; GMFCS, gross motor function classification system; H, height; iv, intravenous; M, male; RT, fractionated radiotherapy;
SD, standard deviation score; TMZ, temozolomide;W, weight.
better tolerated. The requireddaily checkingof ketoneandglucose lev-
els could be achieved without problems. Overall, parents were able to
copewith the situation andwere convinced they did the right thing for
their child.
Parents were satisfied with the high level of support and informa-
tion they received from the research team.
3 DISCUSSION
This study explored feasibility and safety of the KD in three children
with recurrent DIPG and without other treatment options. Feasibility
could not be properly assessed, however, because only twoof the three
patients survived the three-month study period. Both showed deterio-
rationof neurological functioning in the finalweeksof the studyperiod,
suggesting that KD does not impressively reduce tumor growth in the
palliative phase. Interestingly, both patients had a relatively prolonged
survival of 16.5 and 18.7months, respectively, after diagnosis. Yet, it is
not clear whether the prolonged survival can be ascribed to a particu-
lar component or combination of the therapies applied.
As mentioned earlier, studies in mice suggest that KD helps the
host to fight against high-grade glioma when ketones instead of glu-
cose become the main fuel for the brain. The underlying mechanism is
as yet not clarified nor is the best timing to start the KD or the opti-
mal level of ketosis. Mouse models suggest a more profound effect of
KD when combined with RT because sensitization of the tumor cells
by the KD.20 This suggests that in patients with high-grade glioma
(both children and adults), the start of KD as adjuvant therapy to RT
would be more efficient for reduction of tumor load and lengthen-
ing of survival. In addition to this, the ketone levels measured in the
mouse study (>2 mmol/L) were lower than the levels (>2.5 mmol/L)
we achieved in the three children. Even though ketone levels are not
to be 1:1 extrapolated from rodents to humans, the question remains
which level of ketosis should be aimed for. However, the strict regi-
men needed for a substantial level of ketosis puts great demands on
the patient and familywith risk of noncompliance (i.e., effect on palata-
bility and quality of life). This may be more intense during the period
of intensive standard treatment. The prognosis of patients with high-
grade glioma is grim, while alternative and effective treatment options
are lacking. In this line, metabolic alteration by the use of a KD as adju-
vant to standard treatment may be justified.
Severe side effects were not reported. Somemild and transient side
effects, suchas gastrointestinal complaints, occurredmainly during the
diet initiation period and could be resolvedmedically or by dietmodifi-
cation. The reported fatigue and headache may also have been related
to the underlying disease.
After recurrence of DIPG, limited duration of survival can be
expected. This is why a full liquid KD was used, which rapidly induces
ketosis. Adequate ketosis was indeed reached within a very short
period of a week (range, 2–7 days) in all three patients. It cannot
be excluded that this strategy was the cause of the reported gas-
trointestinal complaints during the initiation period. The introduc-
tion of some ketogenic snacks (such as the ketomuffins with same
4:1 diet ratio) during this period may have improved the tolerance
and compliance of the KD while an adequate ketosis was reached.
During the next period, the more liberal KD diet with MCT was well
tolerated.
Our study has some limitations that need to be assessed. First,
by the absence of questionnaires for evaluation of dietary applica-
tion, we used a self-designed, not validated, one. Second, an impor-
tant limitation of our study was the small sample size. BetweenMarch
2010 and May 2015, we could include no more than three patients.
A possible reason is the timing of recruitment. The parents who con-
sulted us (N = 14) were highly motivated to have their child included
in a dietary treatment study when the diagnosis of DIPG had been
recently made—arguing that they at least could personally contribute
to the child's treatment. For children in the palliative stage of dis-
ease, however, most parents lost interest when the child started to
irreversibly lose neurological functions. They concluded that the KD
was not compatible with the best quality of life they wanted for the
child.
In summary, we showed that the KD might be a safe interven-
tion in children with end-stage recurrent DIPG. All parents (n = 3)
included in our study commented that the KD treatment allowed them
to participate more intensively in their child's treatment, which was
highly important to them. Although the small sample size did not allow
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addressing the efficacy of KD, it was proven feasible, and therefore our
experiencesmayhelpdesign aprospective study. Future studies should
focus on the use of modified versions of the KDwith a nutritional com-
position that induces at least a moderate level of ketosis and is started
earlier after diagnosis, preferably as adjuvant to RT.20A less strict diet
might be crucial to recruit a large enough cohort to explore if survival
in DIPG benefits from metabolic alteration when it is combined with
other treatment modalities.
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